Gold Miners ETF (GDX): 1 OUNCE OF GOLD = $37 BANRO CORP...S...

Congo Mining · 2015-05-23T20:23:55.8230000Z

1 OUNCE OF GOLD = $37 BANRO CORP...SYMBOL BAA 100 shares BUYS 1oz LOM PRODUCTION Calculations... Twangiza produced 35,943 ounces of gold in Q1 = approximately 36,000 oz. Annualized production from Twangiza = 144,000 oz Guidance on Namoya Annualized production = 110,000 oz. Total Annualized production = 254,000 oz. Outstanding shares 252,000,000 Shares per oz of production = outstanding shares/production. OUNCES PER SHARE PER YEAR = ANNUALIZED PRODUCTION / OUTSTANDING SHARES 254,000 / 252,000,000 = 0.001007937 ounces per share per year. (0.001 oz /share)(1000shares) = 1oz So 1,000 shares buys 1 ounce of annual production. Note Annual. NI43-101 imminent When then updated mine life is released I expect both Namoya and Twangiza to average about 10 years. If 1,000 shares= 1 ounce of annual production. Then, 1,000 shares buys 10 oz of production for LOM. Thus, 100 shares will purchase 1 oz projected Life of Mine Production Also, @ 0.38 Annualized Margin Cost... Given Gold margin is $681/0z in Q1 ------($380/oz) / ($681/oz) = 0.45521. ***when Namoya has same margin….you’ll be buying a dollar of margin for $0.55 per year. ***Current mine life in the NI43-101 is not inclusive of Transition and Fresh Rock. As was stated on several occasions by management new NI43-101 is imminent. As we all know with further exploration resources will be added and LOM is extended. For precision current LOM listed in the NI43-101’s at Twangiza is 8.76 years and Namoya is 6.74 years. Yet it is still conservative to assume a 10 year LOM given local grade and the inclusion of Transition and Fresh Rock resources.

Play Episode

6min

Proactive - Interviews for investors

Abacus Global Management CEO on 2024 highlights and 2025 targets

Abacus Global Management (NASDAQ:ABL) CEO Jay Jackson takes Proactive's Stephen Gunnion through the company’s strong financial performance in 2024 and its strategic outlook for 2025. The pioneering alternative asset manager reported 69% year-over-year revenue growth for 2024, with the fourth quarter alone seeing a 40% increase. Jackson noted that 2023 was already a record year, and 2024 surpassed that benchmark by over 50%. The company has issued guidance for 2025 that anticipates adjusted net income to rise by between 51% and 68%, driven by continued demand for non-correlated assets. Founded over 20 years ago, Abacus recently rebranded from Abacus Life to better reflect its identity as an alternative asset manager. Jackson explained, “We're an asset manager... and we also own a large institutional asset manager in Luxembourg,” underlining the firm’s expanding global footprint. Growth drivers include strategic acquisitions, expansion of its financial advisor channel, and development in its technology division. Jackson emphasized the role of AI in analyzing health and lifespan data to support financial planning, stating, “Think about the billion scenarios in someone's lifespan… AI helps us understand more accurate outcomes.” Jackson believes 2025 will bring increasing attention to the firm’s asset management operations, complementing its origination and technology capabilities. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications to stay updated. #AbacusGlobal #AlternativeAssets #JayJackson #AssetManagement #LifeInsuranceInvesting #AIinFinance #FinancialPlanning #SmallCapStocks #2025Outlook #InvestorInsights #NonCorrelatedAssets #TechInFinance

Proactive - Interviews for investors

Buru Energy secures strategic deal for LNG development

Buru Energy Ltd CEO Thomas Nador talked with Proactive about the company’s newly announced strategic development agreement with Clean Energy Fuels Australia Pty Ltd (CEFA) to co-develop the Rafael Gas Project. Nador explained that CEFA brings strong midstream and downstream capabilities, backed by I Squared Capital, which manages around $40 billion in assets. "They bring the right credentials, to look after the downstream and midstream elements of the project," he said. Buru, meanwhile, will focus on the upstream side of the Rafael development. The deal is described as a “watershed moment” for the company, as it provides a clear pathway toward developing a long-term gas and condensate business in northwest Western Australia—an area currently dependent on imported energy. Under the agreement, CEFA will fund, build, and operate a small-scale LNG facility on-site, with Buru paying a processing fee over the life of the project. This significantly reduces Buru’s capital exposure to only the upstream infrastructure—namely, two wells, one of which is already in place. A final investment decision is expected in late 2025 or early 2026, with first cash flows anticipated in the second half of 2027. According to Nador, the projected annual free cash flow from the Rafael development is expected to surpass the company’s current market capitalization. For more insights like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future updates. #BuruEnergy #RafaelGasProject #LNGDevelopment #AustralianEnergy #CleanEnergy #GasExploration #CEFA #ThomasNador #ProactiveInvestors #ASXEnergy #NaturalGas #EnergyInfrastructure #I2Capital #UpstreamEnergy #MidstreamDevelopment

Proactive - Interviews for investors

Switch Metals eyes fast-track tantalum output in Côte d'Ivoire as it lists on AIM

Switch Metals Plc (AIM:SWT) CEO Karl Akueson talked with Proactive's Stephen Gunnion about the company’s listing on London’s AIM market and its focus on developing tantalum projects in Côte d'Ivoire. Akueson explained that Switch Metals, a private company he founded, was acquired through a reverse takeover by Oneiro Energy. The company's flagship Issia project hosts tantalum mineralisation, including occurrences of coltan at surface. According to Akueson, this provides an opportunity for near-term production from shallow deposits, with the company aiming to reach output within the next two years. He described tantalum as “a very strategic technology metal… in our mobile phones, laptops, plasma TV, everything we use daily,” highlighting its importance and rarity. Akueson emphasised that 60% of the global supply currently comes from the DRC and Rwanda, and Switch Metals aims to become a significant alternative source. Discussing the decision to list in the UK, Akueson pointed to his personal background and the UK’s long-standing understanding of African production. The £2 million fundraise will support resource definition work at Issia, with plans to quickly define a resource and develop economic parameters to demonstrate value. “Tantalum is probably one of the most critical [metals], and a metal that is unique,” Akueson noted. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #Tantalum #SwitchMetals #CotedIvoireMining #CriticalMinerals #AIMListing #JuniorMining #ResourceDefinition #Coltan #TechMetals #ProactiveInvestors

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Followers	34
Posts	1880
Boards Moderated	0
Alias Born	03/31/2015

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free